All companies
Visit website
20/20 GeneSystems
Public20/20 GeneSystems, Inc.
Biotech · Founded 2000
Early Cancer Detection. Powered by AI.
Post-money valuation ⓘ
$69.9M
As of Apr 2025 · from 20/20 GENESYSTEMS, INC.Preferred Stock 3 · pre-money + amount raised, not a traded price
Total raised
$9,568,727
Across 9 rounds since 2017
Latest share price
$5.34
20/20 GENESYSTEMS, INC.Preferred Stock 3 offering price
Financials
FY2015–FY2025 · from SEC filings · hover any figure for its source$277K
−$1.5M
2018
$288K
−$2.4M
2019
$2.3M
−$2.0M
2020
$9.6M
$2.1M
2021
$11.1M
$2.2M
2022
$1.4M
−$6.4M
2023
$1.8M
−$5.6M
2024
$2.0M
−$3.7M
2025
RevenueNet income — beside revenue when positive, below the line when a loss
Chart shows the most recent 8 fiscal years; 3 earlier years are in the table below.
Metric
FY2015
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024 audited
FY2025 audited
Income statement
Revenue
$908,102
$131,750
$313,207
$277,047
$288,300
$2,330,528
$9,622,332
$11,059,145
$1,424,304
$1,752,343
$2,045,133
Cost of goods sold
$344,807
$102,340
$182,275
$217,595
$263,917
$1,453,354
$4,927,374
$5,937,398
$1,315,166
$1,392,032
$1,440,592
Gross margin
62%
22%
42%
21%
8%
38%
49%
46%
8%
21%
30%
Net income
-$1,871,372
-$708,447
-$1,264,194
-$1,463,105
-$2,425,338
-$2,021,826
$2,071,777
$2,186,875
-$6,391,309
-$5,551,667
-$3,738,821
Taxes paid
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Balance sheet
Cash
$1,097,894
$393,790
$1,040,083
$3,273,494
$636,018
$3,468,192
$3,354,469
$8,807,575
$4,089,461
$1,784,009
$1,025,987
Accounts receivable
$135,693
$21,832
$53,106
$15,488
$32,498
$205,071
$4,215,465
$764,924
$68,834
$135,272
$199,954
Total assets
$1,591,981
$781,469
$1,422,121
$4,105,209
$3,125,886
$4,677,734
$10,272,281
$12,215,021
$6,367,828
$3,584,408
$4,137,357
Short-term debt
$186,731
$0
$964,437
$0
$0
$103,860
$0
$0
$0
$1,011,623
$1,355,078
Long-term debt
$0
$0
$1,500
$0
$0
$40,247
$0
$207,246
$229,164
$1,068,713
$723,848
Total liabilities
$186,731
$705,555
$965,937
$858,149
$0
$144,107
$0
$207,246
$229,164
$2,078,926
$4,156,582
Other
Headcount
—
5
5
18
15
—
45
30
21
20
20
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$42.3M
post-money
$41.4M
post-money
$58.4M
Valuation cap
$69.9M
post-money
Reg A Offering (2020)
Round 3 Reg A? https://www.sec.gov/cgi-bin/browse-edgar?CIK=1139685
20/20 GeneSystems, Inc. Convertible Note 2
20/20 GENESYSTEMS, INC.Preferred Stock 3
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $748.9K / $350K
Raised $0 / $700K
Raised — / $5MPost-money $69.9M
Reg CF annual-report compliance
Not requiredBecame a public company
Filed 7 of 9 annual reports (FY2017–FY2025)
2,824 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 73 filings on EDGARSource: ManualCIK 0001139685Share price $5.34
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.